Beiersdorf to acquire iconic Coppertone & #8482; brand from Bayer
Significant expansion of portfolio will advance Beiersdorf’s leading position as sun care expert / Beiersdorf delivers first major acquisition under its new C.A.R.E.+ strategy / Divestiture enables Bayer to focus on core OTC business (Source: Bayer Company News)
Source: Bayer Company News - May 13, 2019 Category: Pharmaceuticals Source Type: news
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm (for specialized target groups only)
Data from Bayer’s growing oncology portfolio include new analyses on the company’s precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metastatic castration-resistant prostate cancer / Oral presentation on investigational ATR i...
Source: Bayer Company News - May 13, 2019 Category: Pharmaceuticals Source Type: news
Bayer commissions external law firm to investigate Monsanto's stakeholder mapping project and reaffirms its commitment to transparency and fair dealings with all stakeholders
(Source: Bayer Company News)
Source: Bayer Company News - May 12, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA accepts new drug application and grants priority review for darolutamide (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - April 29, 2019 Category: Pharmaceuticals Source Type: news
Bayer & #8217;s Supervisory Board unanimously stands behind Board of Management
(Source: Bayer Company News)
Source: Bayer Company News - April 26, 2019 Category: Pharmaceuticals Source Type: news
& #8220;We made great progress & #8211; both operationally and strategically & #8221;
Bayer now the leader in agriculture / Lawsuits and first verdicts concerning glyphosate weigh on company / Sales and earnings increased in 2018 / Proposed dividend of 2.80 euros marks record payout by Bayer / Successful start to fiscal 2019– outlook confirmed (Source: Bayer Company News)
Source: Bayer Company News - April 26, 2019 Category: Pharmaceuticals Source Type: news
Bayer: strong operational start to the year
Group sales increase 4.1 percent (Fx& portfolio adj.) to 13.015 billion euros / EBITDA before special items advances by 44.6 percent to 4.188 billion euros / Crop Science posts substantial sales and earnings gains following the acquisition / Pharmaceuticals shows encouraging sales and earnings growth / Consumer Health below the prior-year quarter, full-year outlook confirmed / Net income declines as expected by 36.5 percent to 1.241 billion euros, held back by special items related to the acquisition and restructuring / Core earnings per share increase 13.8 percent to 2.55 euros / Business outlook for 2019 confirmed (Sourc...
Source: Bayer Company News - April 25, 2019 Category: Pharmaceuticals Source Type: news
More than 100 Bayer-owned glyphosate safety study reports accessible as Monsanto integration continues
(Source: Bayer Company News)
Source: Bayer Company News - April 8, 2019 Category: Pharmaceuticals Source Type: news
Bayer submits European marketing authorization application for darolutamide (for specialized target groups only)
Third submission for darolutamide in two weeks underscores Bayer’s commitment to fill an unmet need for men with nmCRPC worldwide / Regulatory submission based on positive data from Phase III study ARAMIS (Source: Bayer Company News)
Source: Bayer Company News - March 8, 2019 Category: Pharmaceuticals Source Type: news
Bayer submits darolutamide for marketing authorization in Japan (for specialized target groups only)
Regulatory submission based on positive data from Phase III ARAMIS study (Source: Bayer Company News)
Source: Bayer Company News - March 5, 2019 Category: Pharmaceuticals Source Type: news
Bayer increases sales and earnings & #8211; leader in agriculture after acquisition
Group sales advance 4.5 percent (Fx& portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx& portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx& portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged– Bayer vigorously defending itself against lawsuits/ Net income at 1.69...
Source: Bayer Company News - February 27, 2019 Category: Pharmaceuticals Source Type: news
